You are here

Unique features and findings of the long-term REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) trial

Thursday, 19 September 2019, 12:00 - 13:00, Vilanova Hall

Chair: L. Rydén, SE

H.C. Gerstein, CA: Effect of dulaglutide on serious health outcomes  

M.C. Riddle, US: New findings from the REWIND trial